ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
NCT07513285 · Acurx Pharmaceuticals Inc.
Recruitment statusRecorded edit
− Previous value
Not yet recruiting
+ Updated value
Recruiting
ACXP
Acurx Pharmaceuticals Inc.
Company identity checked against sources
See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.
2Trials in this database
1Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile InfectionNCT04247542 | ACXP | Phase 2 | Completed | 2023-10-03Actual |
| ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile InfectionNCT07513285 | ACXP | Phase 2 | Recruiting | 2027-09-29Estimated |